E
ELEVATION ONCOLOGY INC
NASDAQ: ELEV (Elevation Oncology, Inc.)
最近更新时间: 4小时之前0.350
0.01 (2.91%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Elevation Oncology, Inc. | 混合的 | 混合的 |
AIStockmoo 评分
| 价值 35% | -0.7 |
| AI Insight 参考 | NA |
| 相对估值 参考 | NA |
| 财务健康 参考 | -0.7 |
| 时机 35% | 0.6 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | 0.0 |
| 技术平均移动指标 参考 | 1.5 |
| 聪明钱 30% | 0.0 |
| 分析师共识 参考 | 0.0 |
| 内部交易活动 参考 | NA |
| 市场环境 | ×1.21 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | -22.4% |
| 支柱一致性 | ×0.79 |
| 不计入评分 | |
| 价格波动 参考 | 0.2 |
| 最终评分 | -0.03 |
|
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 0.36% |
| 机构持股比例 | 57.31% |
投资组合